Piper Sandler on Oruka Therapeutics (ORKA): 'Now Is the Time to Own the Name'

March 24, 2026 8:56 AM

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $75.00 price target on Oruka Therapeutics (NASDAQ: ORKA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found